Skip to main content

Resetting neural networks through psilocybin-inspired therapies

Reset Pharma is a neuro-biotechnology company dedicated to improving mental health through novel pathways.

Our Ambition

We exist to help people move beyond the psychological trauma of a life-threatening diagnosis.

Our focus lies where needs are most urgent: helping people overcome demoralization syndrome due to life-altering diseases, such as cancer.

Learn More

Our Science

We are developing transformative, first-in-class, psilocybin-inspired therapies that have the potential to reset neural networks in the brain and reconnect people to meaning in their lives.1,2

Discover the Science

Our Partners

We are breaking new scientific ground in collaboration with leading research institutions, including acquiring a worldwide license from NYU based on the seminal work of Stephen Ross, MD—a leading researcher in the field of psychedelic medicine and psycho-oncology.

To bring our treatment to market, Reset Pharma has established a highly experienced neuro-biotechnology team.

Meet Our Team

Interested in joining
our team?

Career Inquiries

Sign up for our mailing list to learn
more about our latest updates

Stay Informed


1. Grandjean J, Buehlmann D, Buerge M, et al. Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in mice. Neuroimage. 2020;225(2021):117456. doi:10.1016/j.neuroimage.2020.117456

2. Carhart-Harris RL, Roseman L, Bolstridge M, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2021;7(1):13187. doi:10.1038/s41598-017-13282-7